The development of uPAR-targeted stroma-breaking or stroma-penetrating NPs may allow therapeutic agents to overcome stromal barriers and reach tumour cells, which is highly likely to improve the therapeutic effect of current treatment agents and may provide better therapeutic options for patients to reduce tumour-associated metastasis. Here, PLAUR is linked to neoplasm.